[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiometabolic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiometabolic-diseases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,76,104,144,172,196,224,256,282,307,332,365,397,420],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644973","qatar-cardiometabolic-cohort-100644973",false,"NCT07675928","Qatar Cardiometabolic Cohort","Qatar Cardiometabolic Cohort (QCMC)","Inclusion Criteria:\n\n* Qataris\n* Long-term residents (≥15 years of residence in Doha) who are not planning to leave Qatar voluntarily within the next 5 years.\n* Age ≥18 years.\n* English or Arabic speaker.\n* Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.\n\n  1. ASCVD:\n\n     ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.\n\n     i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:\n     1. Coronary Artery Disease (CAD)\n\n        * Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI))\n        * Stable or unstable angina with angiographic stenosis ≥50%\n        * History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG))\n     2. Cerebrovascular Disease\n\n        * Ischemic stroke or transient ischemic attack (TIA)\n        * Symptomatic carotid artery stenosis ≥50% or prior carotid intervention\n     3. Peripheral Arterial Disease (PAD)\n\n        * Intermittent claudication with objective evidence of arterial obstruction\n        * Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI \\\u003C0.9\n     4. Aortic Atherosclerotic Disease •Aortic aneurysm (abdominal or thoracic) of atherosclerotic origin ii.Unequivocally Documented ASCVD on Imaging:\n\n     \u003C!-- -->\n\n     1. Coronary artery calcium (CAC) score \\>100 Agatston units or \\>75th percentile for age and sex\n     2. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery\n     3. Carotid ultrasound or angiography showing plaque or ≥50% stenosis\n     4. Lower-limb CT\u002FMR\u002FDoppler angiography showing atherosclerotic plaque or stenosis ≥50%\n  2. Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines):\n\n     * 10-year fatal\u002Fnon-fatal ASCVD risk ≥10% using SCORE2 (ages 40-69), or ≥15% using SCORE2-OP (≥70 years)\n     * Severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² ii.In diabetic patients (ESC 2023 Diabetes \\& CVD Guidelines):\n     * 10-year cardiovascular risk ≥20% using SCORE2-Diabetes\n     * Severe target organ damage:\n\n  \u003C!-- -->\n\n  1. eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² (regardless of albuminuria)\n  2. eGFR 45-59 mL\u002Fmin\u002F1.73m² with microalbuminuria (UACR 30-300 mg\u002Fg) or proteinuria (UACR \\>300 mg\u002Fg)\n  3. Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy)\n\nExclusion Criteria:\n\n* Type 1 diabetes or monogenic diabetes (e.g., MODY).\n* Pregnancy (self-reported).\n* Active cancer, under medical or radiation therapy or terminal, or cancer in remission \\\u003C 1 year.\n* Chronic immune or chronic infectious diseases.\n* End stage renal disease (ESRD) (estimated glomerular filtration rate \\\u003C15 mL\u002Fmin\u002F1.73m²).\n* Prisoners.\n* Inability or unwillingness to provide informed consent, including language barriers.\n* Mental incapacity.","ALL","18 Years",{"count":19,"type":20},3000,"ESTIMATED","5 Years","OBSERVATIONAL","Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.",[25],"Cardiometabolic Diseases",[27,28,29],"cardiometabolic diseases","atherosclerotic cardiovascular disease","diabetes","NOT_YET_RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":20},"2026-06-01",{"date":38,"type":20},"2036-06-30",{"name":40,"class":41},"Weill Cornell Medical College in Qatar","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100605144","health-chat-for-empowerment-based-lifestyle-planning-for-cardiometabolic-multimorbidity-100605144","NCT07158697","Health Chat for Empowerment-based Lifestyle Planning for Cardiometabolic Multimorbidity","Health Chat for Empowerment-based Lifestyle Planning for Cardiometabolic Multimorbidity (HcELP_CMM) Program: a Randomized Controlled Trial Study","HcELP_CMM","Inclusion Criteria:\n\n1. Adults aged 18 years or above；\n2. Diagnosed with cardiometabolic multimorbidity (CMM), which was defined as co-existing with two or more cardiometabolic diseases, including primary hypertension, type 2 diabetes, stroke, heart diseases (eg. coronary heart disease, arrhythmia, heart failure, myocardial infarction, and cardiac valve diseases), dyslipidemia, and obesity;\n3. Possessed a digital device installed with WeChat, as well as with an internet connection.\n\nExclusion Criteria:\n\n1. Contraindications to exercise according to American College of Sports Medicine (ACSM), such as severe musculoskeletal disorders, severe cardiovascular diseases, or spinal nerve injury;\n2. Diagnosis of psychiatric disease;\n3. Has impaired cognitive function as indicated by an Abbreviated Mental Test Score (AMTS) ≤6;\n4. Has impaired sensory or communication function which hider them participation in this program, such as hearing loss, vision loss, and unable to speak Mandarin.",{"count":52,"type":20},232,"INTERVENTIONAL",[55],"NA","The goal of this study is to:\n\n1. assess the feasibility, acceptability, and the preliminary effects of the health chat for empowerment-based lifestyle planning for CMM (HcELP\\_CMM);\n2. examine the short-term effects of the HcELP\\_CMM program on lifestyle behaviors, cardiometabolic indicators, symptom burden, health related quality of life (HRQoL), psychological well-being, and physical function in patients with CMM;\n3. examine the long-term effects of the HcELP\\_CMM program on lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM.\n\nThe main questions it aims to answer are:\n\n1. If the HcELP\\_CMM program is feasible and acceptable?\n2. If the HcELP\\_CMM program has the potential to improve the lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM compared to the usual care group in the short-term？\n3. If the HcELP\\_CMM program has the potential to improve the lifestyle behaviors, cardiometabolic indicators, symptom burden, HRQoL, psychological well-being, and physical function in patients with CMM compared to the usual care group in the long-term？",[25,58],"Multimorbidity",[60,61,62,63,64],"Cardiometabolic multimorbidity","Empowerment","Patient-centered","Self-management","Intervention","RECRUITING","2026-05-06",{"date":68,"type":34},"2026-05-11",{"date":70,"type":34},"2025-09-08",{"date":72,"type":20},"2027-02-05",{"name":74,"class":41},"The University of Hong Kong",3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":53,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":42},"100622672","impact-of-circadian-exercise-on-metabolic-dysfunction-associated-steatotic-liver-disease-in-postmenopausal-women-100622672","NCT07386665","Impact of Circadian Exercise on Metabolic Dysfunction-Associated Steatotic Liver Disease in Postmenopausal Women","Inclusion Criteria:\n\n* Women aged 45-75 years, postmenopausal for at least two years (stage +1a)\n* Body Mass Index (BMI) \\> 25 and \\\u003C 40 kg\u002Fm²\n* Diagnosed hepatic steatosis (via ultrasound hyperechogenicity, FibroScan CAP score \\>280, or histological confirmation)\n* Sedentary lifestyle (no regular structured exercise)\n* Willingness to be randomized and adhere to study procedures, including all assessments and visits\n* Sufficient Spanish proficiency to understand and follow study instructions\n* Consent to store biological samples for future research\n* Participants should have a healthy circadian rhythm\n\nExclusion Criteria:\n\n* Contraindications for MRI (e.g., claustrophobia, pacemaker, metal implants)\n* History of major cardiovascular, endocrine, neurological, or kidney disease, or any clinical abnormalities (to be judged by the study physician)\n* First-degree family history of sudden cardiac death\n* Alcohol or substance abuse\n* Psychiatric, psychotic, eating, or sleep disorders (to be judged by the study physician)\n* Prior bariatric surgery, diagnosed HIV\u002FAIDS, or inflammatory\u002Fautoimmune diseases\n* Cancer or any medical condition where exercise is contraindicated (to be judged by the study physician)\n* Recent or unstable metabolic conditions (e.g., diabetes, recent medication changes, or use of drugs affecting metabolism)\n* Recent (\\\u003C3 months) use of antibiotics, statins, glucocorticoids, hormonal therapies, amiodarone, or myelosuppressive agents\n* Participation in weight-loss programs or special diets (e.g., ketogenic, high-carb)\n* Shift workers or caregivers with frequent nocturnal disruptions","FEMALE","45 Years","75 Years",{"count":86,"type":20},63,[55],"Type of Study: Clinical Trial\n\nGoal: The goal of this clinical trial is to investigate how performing exercise at different times of day (morning vs. evening) affects liver fat, cardiometabolic health, and gut microbiota in postmenopausal women.\n\nParticipant Population\u002FHealth Conditions: The study will involve 63 sedentary postmenopausal women (aged 45-75) diagnosed with metabolic dysfunction-associated steatotic liver disease.\n\nMain Questions: The main questions this study aims to answer are:\n\n* Does morning exercise reduce hepatic fat more effectively than evening exercise?\n* How does time-of-day-specific exercise influence cardiometabolic markers?\n* Do changes in gut microbiota contribute to the metabolic effects of exercise timing?\n\nParticipants Will:\n\nBe randomized into one of three groups: morning exercise, evening exercise, or a usual-care control group.\n\nFollow the assigned regimen for 12 weeks. The exercise groups will perform supervised aerobic and resistance training three times per week.\n\nProvide blood, stool, and imaging data before and after the intervention to determine the effects of the intervention.\n\nComparison Group:\n\nResearchers will compare the effects of morning vs. evening exercise (and usual care) on hepatic fat reduction and cardiometabolic improvement, as well as changes in gut microbiota.",[90,25,91],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Exercise",[91,93,94,95],"Metabolism","Health","Women","2026-05-04",{"date":98,"type":34},"2026-05-08",{"date":36,"type":20},{"date":101,"type":20},"2027-12",{"name":103,"class":41},"Universidad de Almeria",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":82,"minAge":17,"maxAge":83,"enrollmentInfo":112,"targetDuration":114,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":128,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":42},"100636441","cardiometabolic-disease-and-substrate-metabolism-100636441","NCT07565727","Cardiometabolic Disease and Substrate Metabolism","Cardiometabolic Disease, Substrate Metabolism, and Abnormal Placental Pathology: a Multimodal Maternal-Fetal Study","CAP","Inclusion Criteria:\n\n* Age 18-45\n* Any pre-pregnancy BMI\n* At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines\n* Willingness to adhere to aspirin therapy\n* Willingness to undergo 2h OGTT for serum collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.\n* Gestational age at enrollment \\\u003C18 weeks\n* Ability to speak, read, and communicate via English\n\nExclusion Criteria:\n\n* Type 2 Diabetes Mellitus\n* Type 1 Diabetes Mellitus\n* Current gestational diabetes mellitus\n* Current\u002Factive platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura\u002FITP, thrombotic thrombocytopenic purpura\u002FTTP, von Willebrand disease, etc.)\n* Thrombophilia\n* Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)\n* Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)\n* Current or recent use of steroids\n* Current use of prophylactic or therapeutic anticoagulation\n* Medical contraindication to aspirin therapy\n* Molar pregnancy\n* Renal disease\n* Inability or unwillingness to give informed consent\n* Current psychiatric illness\u002Fsocial situation that would limit compliance with study requirements, as determined by the principal investigators",{"count":113,"type":20},50,"9 Months","This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.",[117,118,119,120,121,122,25,123,124,125,126,127],"Preeclampsia","Gestational Diabetes Mellitus (GDM)","Preeclampsia (PE)","Preeclampsia (PE) Risk","Gestational Diabetes","Gestational Diabetes Mellitus in Pregnancy","Insulin Resistance","Placental Dysfunction","Pregnancy","Pregnancy Complications","Gestational Complications",[129,130,117,121,131,132,133,134,135],"Cardiometabolic disease","Substrate metabolism","Insulin resistance","HOMA-IR","Lipid oxidation","Placental dysfunction","Chorangiosis","2026-04-27",{"date":96,"type":34},{"date":139,"type":34},"2025-12-10",{"date":141,"type":20},"2027-08",{"name":143,"class":41},"University of Tennessee Graduate School of Medicine",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":151,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":53,"phases":154,"briefSummary":155,"conditions":156,"keywords":162,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":42},"100455859","genesis-genotype-guided---natriuretic-peptides---cardiometabolic-health-study-100455859","NCT05216042","GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study","Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18; an equal number of Males and Females\n* Consent to the collection of genetic material\n* Willing to adhere to the study protocol\n\nExclusion Criteria:\n\n* Age \\\u003C18, at screening.\n* BMI \\>45 kg\u002Fm2.\n* Blood pressure more than 140\u002F90 mmHg.\n* Participants who are taking more than 2 hypertension medications.\n* History of diabetes or fasting plasma glucose \\>126 mg\u002Fdl or HbA1C\\>=6.5% or prior treatment with antidiabetic medication.\n* Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Anemia (men, Hct \\\u003C 38%; women, Hct \\\u003C36%)\n* Inability to exercise on a treadmill",true,{"count":153,"type":20},200,[55],"Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \\~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \\~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.",[157,158,25,159,160,91,161],"Cardiovascular Diseases","Natriuretic Peptides","Energy Expenditure","Glucose Metabolism","Obesity",[158,157,160,159,91,161],"2026-04-03",{"date":165,"type":34},"2026-04-09",{"date":167,"type":34},"2022-04-01",{"date":169,"type":20},"2027-04-30",{"name":171,"class":41},"University of Alabama at Birmingham",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":151,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":53,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100602060","genetic-architecture-of-natriuretic-peptides-and-blood-pressure-response-100602060","NCT07118592","Genetic Architecture of Natriuretic Peptides and Blood Pressure Response","Inclusion Criteria:\n\n* Age more than or equal to 18 years\n* Consenting to collection of genetic material and willing to adhere to study protocol\n* Stage I\u002FII Hypertension (Systolic blood pressure: 130-159 and Diastolic blood pressure: 80-99 mm Hg)\n\nExclusion Criteria:\n\n* Body mass index (BMI) more than 45 kg\u002Fm2\n* History of uncontrolled hypertension (i.e., Systolic blood pressure more than or equal to 160 mmHg and\u002For Diastolic blood pressure more than or equal to 100 mmHg)\n* If taking more than or equal to 2 blood pressure medications at the time of screening\n* Systolic blood pressure more than 180 and\u002For Diastolic blood pressure more than or equal to 120 mmHg at any point in the study\n* Present or past history of major cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, heart failure, stroke, transient ischemic attack, or seizure.\n* Pregnant or breastfeeding individuals\n* History of kidney disease\n* History of insulin requiring diabetes\n* Estimated glomerular filtration rate less than 60ml\u002Fmin\u002F1.73 m2, albumin creatinine ratio more than or equal to 30 mg\u002Fg\n* Hepatic transaminase levels more than 3 times the upper limit of normal\n* Anemia (men, Hb less than 13 g\u002FdL; women, Hb less than 12 g\u002FdL)",{"count":153,"type":20},[55],"Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.",[182,25],"Hypertension (HTN)",[184,185,186,187],"Hypertension","Natriuretic peptides","Polygenic risk score","Cardiometabolic diseases","2026-03-06",{"date":190,"type":34},"2026-03-10",{"date":192,"type":20},"2026-09-01",{"date":194,"type":20},"2030-12-01",{"name":171,"class":41},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":53,"phases":206,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":42},"100561681","nt-probnp-based-heart-failure-screening-and-prevention-trial-in-patients-with-type-2-diabetes-strong-dm-study-100561681","NCT06593327","NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study","Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus","STRONG-DM","Inclusion Criteria:\n\n* Primary Care Provider that sees diabetes patients in clinic\n\nExclusion Criteria:\n\n* Provider does not see patients with Diabetes",{"count":205,"type":20},300,[55],"A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.",[209,210,211,25],"Type 2 Diabetes","Diabetic Cardiomyopathy","Heart Failure",[213,211,214],"Pragmatic Clinical Trial","Cardiovascular Prevention","2026-02-26",{"date":217,"type":34},"2026-02-27",{"date":219,"type":34},"2025-02-10",{"date":221,"type":20},"2027-12-15",{"name":223,"class":41},"University of Texas Southwestern Medical Center",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":151,"sex":16,"minAge":83,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":53,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":42},"100607524","sustainable-diets-and-cardiometabolic-health-100607524","NCT07189676","Sustainable Diets and Cardiometabolic Health","PLANETDIET: Sustainable Diets and Cardiometabolic Health: a Multi-omics Approach in a Randomized Controlled Trial (RCT)","PlanetDiet","Inclusion Criteria:\n\n* Adults (males and females) between 45 and 70 years of age at the time of inclusion.\n* Participants must have at least two metabolic alterations: 1) Waist Circumference (WC) \\>102 cm (males) or \\>88 cm (females); 2) self-reported medication for blood pressure or blood pressure \\>130\u002F85 mmHg; 3) self-reported prediabetes or non-fasting plasma glucose 140-199 mg\u002FdL (prediabetes); 4) self-reported lipid-lowering medication or diagnosis of impaired blood lipids (triglycerides: ≥ 150 mg\u002FdL; and HDL: men: \\\u003C 40 mg\u002FdL and women: \\\u003C 50 mg\u002FdL).\n* Participants are not institutionalized, able to read and provide consent before participation, and willing to attend in-person visits at the study site.\n* Participants should have access to a smartphone and computer, or tablet and must be internet-literate.\n* Understand Danish both in writing and when spoken.\n\nExclusion Criteria:\n\n* Participants with any serious illness or history of cancer within the past 5 years (except adequately treated localized basal cell skin cancer or in situ uterine cervical cancer).\n* Diagnosed with diabetes mellitus, CVD event (myocardial infarction, revascularization procedure, or stroke), or atrial fibrillation.\n* Participants with diagnosed psychiatric conditions or cognitive impairment.\n* Current smokers including all kinds of nicotine-containing products.\n* BMI \\>35 kg\u002Fm2.\n* Known or suspected abuse of alcohol or recreational drugs. Regular alcohol consumption exceeding the Danish national guidelines (i.e., more than 10 standard drinks per week or more than 4 drinks on any single day) will be excluded.\n* Pregnancy or planning a pregnancy in the next year.\n* Not willing to consume chicken and fish or not willing to make dietary changes related to the intervention.\n* Participants with multiple food allergies that could hinder adherence to the intervention.\n* Any other issue that makes the project responsible (PI or medical responsible) doubt the eligibility of the volunteer.","70 Years",{"count":234,"type":20},180,[55],"This study aims to investigate the effects of sustainable diets on traditional and novel cardiometabolic risk factors.\n\nThe primary objective is:\n\n• To test the effects of a sustainable diet on traditional cardiometabolic risk factors, specifically, a metabolic health score.\n\nThe secondary objectives are:\n\n* To test the effects of sustainable diets on blood lipids, inflammatory markers, glucose markers, and anthropometric and body composition markers.\n* To test the effect of sustainable diets on circulating metabolomic profiles.\n* To test the effects of sustainable diets on circulating proteomic profiles.\n\nParticipants will receive dietary interventions of a sustainable health diet, namely the PHD diet (Planetary Health Diet), an ovo-lacto-vegetarian diet, or a habitual diet following general recommendations for a healthy diet without advice on consumption of animal products. The three-arm parallel RCT will involve adults (45-70 years old) at cardiovascular risk.\n\nThe primary hypothesis is that targeted interventions to adopt sustainable diets will have beneficial effects on cardiometabolic biomarkers, metabolomic, and proteomic profiles, compared to the habitual diet in individuals at cardiovascular risk.",[25],[239,240,241,242,243,244,245,246],"metabolomics","proteomics","sustainable diets","cardiometabolic health","nordic diet","randomised controlled trial","cardiometabolic risk factors","planetary health diet","2025-12-17",{"date":249,"type":34},"2025-12-24",{"date":251,"type":34},"2025-11-24",{"date":253,"type":20},"2027-04",{"name":255,"class":41},"University of Copenhagen",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":53,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":42},"100604384","impact-of-earplugs-on-mechanisms-of-noise-related-cardiovascular-disease-100604384","NCT07148817","Impact of Earplugs on Mechanisms of Noise-Related Cardiovascular Disease","Impact of Personal Mitigation on Mechanisms Linking Transportation Noise Exposure to Cardiometabolic Disease","Inclusion Criteria:\n\n* Describe feeling annoyed by transportation noise exposure or have high residential noise exposure (\\>45 dBA average over 24 hours) using the United States Department of Transportation Map\n* Known stable atherosclerosis or at least one typical risk factor (i.e., hypertension, diabetes, active smoking, or hyperlipidemia)\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* History of stroke, brain surgery, or seizure\n* Use of certain CVD medications (e.g., beta-blockers, high-intensity statins \\[e.g., rosuvastatin 20\u002F40 mg and atorvastatin 40\u002F80 mg\\], PCSK-9 inhibitors)\n* Psychiatric or cardiovascular medication change within 3 months (i.e., stable regimen is allowed)\n* Unstable blood pressure or cardiac arrhythmia\n* Current use of personal noise mitigation techniques or involvement in stress management program\n* Moderate\u002Fsevere alcohol\u002Fsubstance use disorder\n* Current mania\u002Fpsychosis\n* Weight \\>300 lbs.\n* Claustrophobia\n* Pregnancy\n* Metal implants\n* Uncontrolled hyperglycemia (HgbA1c\\>7.5%)\n* Subjects who have had significant radiation exposure as part of research (\\>2 nuclear tests, computed tomography images, or fluoroscopic procedures) during the preceding 12-months","65 Years",{"count":265,"type":20},26,[55],"Noise from cars, planes, and trains affects all people and has been associated with heart disease. Almost 30% of Americans are exposed to harmful levels of noise and noise accounts for the loss of more than one million healthy life years per year in Europe. Noise causes stress and may be most dangerous when it happens at night. The mechanisms linking noise to heart disease involve changes in the brain and the \"fight or flight\" response. These changes lead to inflammation and blood vessel disease. However, there are few laws that restrict noise and it is not addressed in medical care. Further, as cities and industries grow, noise continues to increase. Moreover, noise often occurs in areas that are also exposed to other stressors like high air pollution and low income. Yet, there is little research on noise, and it is not known if lowering noise exposure helps heart health. The investigators will use imaging to test if earplugs that block noise improve stress symptoms and changes in the the brain, blood vessels, and stress pathways that lead to disease. The investigators expect that people who use earplugs will have lower measures of stress and heart disease at follow-up. The study will include 26 people with heart disease risk with high noise exposure or who are annoyed by noise. At the first visit, subjects will have imaging of the brain and blood vessels and will have assessments of stress, inflammation, and the \"fight or flight\" response. They will be assigned to use earplugs or not after the first visit. After 6 months, imaging and other testing will be repeated. It will help to understand how noise impacts the body and whether the effects can be changed. It may also identify important treatments to prevent heart disease in people exposed to noise. By testing if the adverse effects of noise can be lowered with earplugs, this project supports the AHA's mission to be a force for a world of longer and healthier lives.",[25,269],"Noise Exposure",[271,25,272],"Transportation Noise","Earplugs","2025-10-31",{"date":275,"type":34},"2025-11-03",{"date":277,"type":34},"2025-10-15",{"date":279,"type":20},"2028-06-30",{"name":281,"class":41},"Massachusetts General Hospital",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":151,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":290,"conditions":291,"keywords":296,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":42},"100608742","sarcopenia-metabolic-diseases-and-integrated-aging-longitudinal-evaluation-smile-100608742","NCT07205510","Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)","Inclusion Criteria:\n\nAdults aged 18 and over\n\nExclusion Criteria:\n\n1. Does not cooperate in signing the informed consent form;\n2. Does not possess legal capacity;\n3. In a state of loss of consciousness;\n4. Suffering from severe mental illness, unable to communicate normally;\n5. The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion.",{"count":289,"type":20},10000,"This study aims to establish an ambispective cohort platform centered on the pathological axis of \"sarcopenia-metabolic disorders-aging progression\", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.",[292,293,294,295,25],"Sarcopenia","Metabolic Diseases","All-cause Mortality","Aging",[292,293,295,297,25],"All-cause mortality","2025-09-25",{"date":300,"type":34},"2025-10-03",{"date":302,"type":34},"2020-12-01",{"date":304,"type":20},"2040-12-31",{"name":306,"class":41},"RenJi Hospital",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":316,"studyType":22,"phases":4,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":42},"100595871","real-world-data-of-cardiometabolic-protection-100595871","NCT07038083","REal-world Data of CARdiometabolic ProtEcTion","RED-CARPET","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Patients with clinical diagnosis of metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia.\n\n  1. Hypertension and normal high blood pressure: Three standardized blood pressure measurements in the clinic on different days, and all the blood pressure values of the three measurements were systolic blood pressure ≥ 120 mmHg and\u002For diastolic blood pressure ≥ 80 mmHg;\n  2. Diabetes: ① Typical symptoms of diabetes, and any of the following: ② Random blood glucose ≥ 11.1 mmol\u002FL; ③ Fasting blood glucose (FPG) ≥ 7.0 mmol\u002FL; ④ OGTT 2-hour postprandial blood glucose ≥ 11.1 mmol\u002FL; ⑤ HbA1c ≥ 6.5%;\n  3. Obesity and overweight: Body mass index (BMI) ≥ 24 kg\u002Fm²;\n  4. Dyslipidemia: At least one of the following lipid indicators is abnormal: ① Total cholesterol (TC) ≥ 6.2 mmol\u002FL; ② Low-density lipoprotein cholesterol (LDL-C) ≥ 4.1 mmol\u002FL; ③ High-density lipoprotein cholesterol (HDL-C) \\\u003C 1.0 mmol\u002FL; ④ Triglyceride (TG) ≥ 2.3 mmol\u002FL; ⑤ Lipoprotein(a) ≥ 30 mg\u002FdL;\n  5. Hyperuricemia: The fasting blood uric acid levels on two different days were \\> 420 μmol\u002FL (7 mg\u002FdL) in men and \\> 360 μmol\u002FL (6 mg\u002FdL) in women.\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent.",{"count":315,"type":20},40000,"15 Years","This study is a single-center, historical prospective cohort study including patients diagnosed with metabolic cardiovascular disease, including hypertension, diabetes, obesity, dyslipidemia, hyperuricemia. The primary outcome of the study is all-cause death and cardiovascular death, and the secondary outcome is major adverse cardiovascular events. We aim to measure associations of established or suspected cardiometabolic disease (CMD) risk factors and cardiovascular disease outcomes in a real-world representative cohort.",[25],[25,320,321,322],"all-cause mortality","Cardiovascular death","Major adverse cardiovascular events","2025-06-18",{"date":325,"type":34},"2025-06-26",{"date":327,"type":34},"2014-01-01",{"date":329,"type":20},"2044-01-01",{"name":331,"class":41},"Sun Yat-sen University",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":151,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":42},"100574173","sleep-disordered-breathing-and-multimorbidity-the-xiangya-sdb-cohort-study-100574173","NCT06755840","Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study","Inclusion Criteria:\n\n* 1\\) Participants who were suspected of sleep disordered breathing must complete at least one overnight sleep monitoring at the Sleep Medicine Center at Xiangya Hospital.\n* 2\\) Participants can finish any assessment for each comorbid system by questionnaires, scales, physical examinations and tests, etc. independently or with the assistance.\n* 3\\) Participants agreed to participate in this study with signing an informed consent form.\n\nExclusion Criteria:\n\n* Participants who refused to participate in this study or whose clinical data was lost.",{"count":339,"type":20},15000,"Sleep disordered breathing (SDB) is one of the most common sleep disorders, including obstructive sleep apnea (OSA), central sleep apnea (CSA), sleep-related hypoventilation, hypoxemia, etc., with OSA being the most prevalent. Also, SDB shows high comorbidities with multisystem diseases. Furthermore, compared to patients with pure SDB, those comorbid with SDB and other disorders like cardiometabolic dysfunction and cognitive impairment experience poorer quality of life, higher rate of disease progression and mortality, and a greater economic burden. Currently, there are limited cohorts to study the associations between SDB and multisystem diseases. The aim of this study is to establish an ambispective clinical cohort for SDB in Xiangya hospital from central-south China (Xiangya Sleep Disordered Breathing Cohort, Xiangya SDB cohort) including retrospective part and prospective part, which covers multi-dimensional data of sleep monitoring, demographic, daily behaviors, clinical manifestations and comorbidities status, life quality, treatment information and evaluation, etc. by self-reported questionnaires and objective assessments and tests. Besides, whole peripheral blood is drawn for following biomarkers study and omics analysis. The main goal is to achieve precise management of SDB and related multimorbidity, containing to early identify risk individuals for multisystem impairment, significantly improve their prognosis and ultimately enhance overall health. In detail: first, to reveal how multisystem impairment related to SDB evolves; second, to identify which indicators closely involve system dysfunction due to SDB; third, to build an efficient model and a cost-effective platform to screen high-risk population and tract therapeutic effect.",[342,343,25,58,344],"Sleep Disordered Breathing (SDB)","Sleep Apnea","Neurodegenerative Diseases",[346,347,348,349,350,351,352,353,354,355],"sleep disordered breathing","obstructive sleep apnea","central sleep apnea","cardiovascular diseases","metabolic diseases","respiratory diseases","nervous system diseases","mental disorders","neoplasms","multimorbidity","2025-04-01",{"date":358,"type":34},"2025-04-03",{"date":360,"type":34},"2025-01-15",{"date":362,"type":20},"2035-10-31",{"name":364,"class":41},"Xiangya Hospital of Central South University",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":373,"maxAge":84,"enrollmentInfo":374,"targetDuration":4,"studyType":53,"phases":375,"briefSummary":376,"conditions":377,"keywords":385,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100585834","preventative-screening-and-health-coaching-in-a-food-insecure-population-100585834","NCT06907524","Preventative Screening and Health Coaching in a Food Insecure Population","Community-Based Preventative Cardiometabolic Screening and Health Coaching- A Prospective Study","HEALTHCOACH","Inclusion:\n\nPatient is a participant at a CHI sponsored, community screening event Patient provides informed consent and willingness to participate for the duration of the study English or Spanish speaking Age 40-75 years old At least 1 cardiometabolic risk factor at suboptimal level\n\nDefined as one or more of the following at initial screening:\n\nBlood Pressure (BP):\n\nSystolic BP greater than 130mmHg and\u002For diastolic BP greater than 80mmHg. Obesity: body mass index (BMI) greater than 30 〖kg\u002Fm〗\\^2\n\nDyslipidemia:\n\nTotal cholesterol greater than 200 mg\u002FdL Triglycerides greater than 150 mg\u002FdL Low density lipoprotein (LDL) greater than 130 mg\u002FdL High density lipoprotein (HDL) less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women Hemoglobin A1c greater than or equal to 5.7% 10-year ASCVD score greater than 5% Access to a telehealth compatible device\n\nExclusion:\n\nAdults unable to provide informed consent or unwilling to participate for study duration Speaks language other than English or Spanish Younger than 40 years old or older than 75 years old All cardiometabolic risk factors at optimal levels No telehealth compatible device Pregnant patients","40 Years",{"count":153,"type":20},[55],"The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are:\n\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke?\n* Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes?\n* Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare?\n\nResearchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors.\n\nParticipants will:\n\n* Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6.\n* Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare\n* Keep a log of their blood pressure",[378,25,379,380,184,381,382,383,384],"Cardiovascular Disease Prevention","Cardiovascular Risk Factor","Cardiovascular Risk Score","Hyperlipidemia","Diabetes","Lifestyle Modification","Health Coaching",[378,386,184,381,382,383,384,380,387,379,388],"Cardiometabolic Disease Screening","Atherosclerotic Cardiovascular Disease Risk Score","Cardiometabolic Disease","2025-03-26",{"date":391,"type":34},"2025-04-02",{"date":356,"type":20},{"date":394,"type":20},"2027-07-01",{"name":396,"class":41},"Rush University Medical Center",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":151,"sex":16,"minAge":404,"maxAge":405,"enrollmentInfo":406,"targetDuration":408,"studyType":22,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":42},"100456433","prenatal-programming-of-childhood-obesity-and-cardio-metabolic-disorders-100456433","NCT05223530","Prenatal Programming of Childhood Obesity and Cardio Metabolic Disorders","Prenatal Programming of Childhood Obesity and Cardio Metabolic Disorders - Role of Maternal Obesity, Pregnancy Complications, and Maternal-fetal Metabolome","Inclusion Criteria:\n\n* all mothers participated originally in the PREDO or the RADIEL studies during pregnancy and with delivery during this index pregnancy\n\nExclusion Criteria:\n\n\\-","11 Years","55 Years",{"count":407,"type":20},750,"7 Days","This is a prospective 11-17 -years follow-up of two existing pregnancy cohort (PREDO) and prevention (RADIEL) studies. The main objective is to investigate the associations between maternal overweight, obesity, hypertensive disorders in pregnancy, gestational diabetes, and maternal-fetal metabolome, child's birth outcomes, and overweight and obesity and cardio metabolic health outcomes in childhood and adolescence. During this follow-up study, the mothers and their 11-17-year-old children are invited for a study visit and their cardio metabolic health is studied by many different methods.",[25,161],"2024-12-09",{"date":413,"type":34},"2024-12-10",{"date":415,"type":34},"2022-02-25",{"date":417,"type":20},"2026-12",{"name":419,"class":41},"Helsinki University Central Hospital",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":151,"sex":82,"minAge":17,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":53,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":42},"100548829","deciphering-a-novel-and-unique-brown-adipose-tissue-depot-in-women-100548829","NCT06426082","Deciphering a Novel and Unique Brown Adipose Tissue Depot in Women","Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women","DEBATE","Inclusion Criteria:\n\n* 18-22 years of age women.\n* BMI between ≥18 and \\\u003C25 kg\u002Fm2\n* Are willing to be randomized to either of these 4 groups.\n* Must be sedentary (i.e., do not perform exercise or go to the gym).\n* Participants should have regular menstrual cycles.\n* Must be willing to adhere to all study procedures, including attendance at all study visits.\n* Must be willing to have biological samples stored for future research.\n* Must accept the use of the Period Calendar and Google Fit Apps on their mobile phones.\n\nExclusion Criteria:\n\n* Diabetes mellitus (determined based on fasting glucose levels defined by ADA criteria).\n* Any other active endocrine disease (thyroid disease, any signs of Cushing's syndrome, adrenal disease and lipid-associated disorders such as familial hypercholesterolemia).\n* Any cardiac disease (i.e., ischemic cardiac disease, arrhythmias, severe heart failure).\n* Use of medication known to influence glucose and\u002For lipid metabolism or brown fat activity (e.g., beta-blockers, antidepressants, corticosteroids).\n* Use of medication shown to increase risk of hypokalemia after salbutamol administration (e.g., xanthine derivatives, steroids and diuretics).\n* Clinically relevant abnormalities in clinical chemistry or electrocardiogram (ECG) at screening (to be judged by the study physician).\n* A first-degree family member with sudden cardiac death.\n* Any chronic renal or hepatic disease.\n* Any other contra-indications for the use of salbutamol or propranolol.\n* Abuse of alcohol or other substances.\n* Smoking.\n* Current participation in another research projects that may influence the current research project.\n* Use of beta-adrenergic receptor agonists (e.g., asthma).\n* Polycystic ovary syndrome.\n* Diagnosed psychotic conditions.","22 Years",{"count":430,"type":20},40,[55],"Type of Study: Clinical Trial\n\nGoal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.\n\nParticipant Population\u002FHealth Conditions: The study will involve 40 young, lean adult women.\n\nMain Questions: The main questions this study aims to answer are:\n\n* Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?\n* What is the secretory function of these adipocytes?\n* How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?\n\nParticipants Will:\n\nBe randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.\n\nFollow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.\n\nUndergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.\n\nComparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.",[25],[435,436,437,438,439],"brown adipose tissue","cold exposure","hot exposure","dorsocervical fat","exercise","2024-05-20",{"date":442,"type":34},"2024-05-23",{"date":444,"type":20},"2024-11-01",{"date":446,"type":20},"2026-08",{"name":103,"class":41}]